Cornelia de Lange Syndrome

Overview

Cornelia de Lange syndrome (CdLS) is a rare genetic developmental condition that can affect growth, learning, behavior, facial appearance, limbs, hearing, digestion, and other organs. It is most often caused by a disease-causing change in NIPBL, but changes in several other genes involved with the cohesin system—a protein system that helps organize DNA and regulate gene activity—can also cause CdLS. Severity varies widely, from relatively subtle features to major congenital differences and substantial intellectual disability. GeneReviews: Cornelia de Lange Syndrome

Prognosis depends chiefly on the individual’s genetic cause and medical complications, especially feeding and swallowing problems, gastroesophageal reflux, heart differences, respiratory illness, seizures, and developmental needs. There is currently no approved treatment that corrects the underlying genetic and developmental cause of CdLS; standard care is coordinated, lifelong, multidisciplinary support including feeding and gastrointestinal care, developmental, speech, occupational and physical therapies, behavioral and communication support, and treatment or surgery for specific medical complications. GeneReviews: Cornelia de Lange Syndrome

Scope of Recent Research (2020–present)

Since 2020, CdLS research has become more mechanistically precise, using gene-edited patient stem cells, brain organoids, animal models, sequencing, and early clinical studies to connect cohesin dysfunction with altered gene regulation, neural development, cell death, and behavior. The field remains small and is not yet close to a whole-body cure: current translational work is focused on either correcting a specific mutation in cells or improving downstream biological and behavioral effects with repurposed medicines, particularly lithium and N-acetylcysteine (NAC). CRISPR-corrected CdLS stem cells Lithium in 2D and 3D CdLS models NAC CdLS trial

Major Breakthroughs and Emerging Therapies

Gene editing and gene restoration. A 2022 proof-of-concept study corrected a specific NIPBL mutation in induced pluripotent stem cells (iPSCs), which are patient-derived cells reprogrammed into an embryonic-like state. Researchers compared several CRISPR-based editing methods and used homology-directed repair to generate corrected cell clones from a patient’s cells. This is an important scientific milestone because it creates matched “before and after” models of CdLS, but it was performed only in laboratory cells—not in patients—and does not yet provide a delivery method or demonstrate that correcting cells after birth reverses established CdLS features. CRISPR-corrected CdLS stem cells

WNT-pathway modulation with lithium. The most developed drug-repurposing strategy targets the WNT signaling pathway, a major regulator of embryonic and neural development. In 2021, lithium restored proliferation and differentiation measures in mouse neural stem-cell and other CdLS-related models by activating WNT signaling. Lithium as a CdLS therapeutic strategy A 2026 follow-up extended this work into human iPSC-derived neural precursor cells and three-dimensional brain organoids; lithium partly normalized cell survival, neuronal differentiation, and gene-expression patterns in an experimental model in which HDAC8 activity was inhibited to mimic cohesin dysfunction. These findings support lithium as a candidate for symptom modification, not evidence of a cure, because the models do not reproduce every genetic subtype or lifelong, multi-organ feature of CdLS. Lithium in 2D and 3D CdLS models

Oxidative-stress and neurobehavioral approaches. NAC is an antioxidant and glutamate-modulating medicine being tested for repetitive and self-injurious behaviors in CdLS. The rationale comes from evidence that cohesin-related dysfunction can be associated with oxidative stress and altered neuronal development; however, NAC is intended to reduce specific behavioral symptoms rather than repair the causative gene or reverse congenital differences. NAC CdLS trial

Precision models rather than direct therapies. Recent patient-derived iPSC research has shown that a NIPBL variant can alter chromatin accessibility—the openness of DNA regions that control whether genes can be used—and impair differentiation toward liver cells. These studies help identify biological targets and safety biomarkers for future therapies, but they are discovery platforms rather than treatments. NIPBL iPSC hepatocyte model

Clinical Trials and Experimental Approaches

The University of Milan is sponsoring CLoSER (NCT06789783), a multicenter, non-commercial Phase 2/3 study of lithium carbonate in an estimated 34 people with genetically confirmed NIPBL-related CdLS. The study began in May 2024 and is designed to assess behavioral, cognitive, communication, sleep, quality-of-life, safety, and laboratory outcomes; the registry lists study completion in December 2026. No posted efficacy results were available in the registry record reviewed for this report. CLoSER lithium trial

Johns Hopkins University, with the Cornelia de Lange Syndrome Foundation as collaborator, is sponsoring a randomized, double-blind, placebo-controlled crossover Phase 2 pilot study of NAC for repetitive and self-injurious behaviors (NCT04381897). The registry lists an estimated enrollment of 10 participants and an estimated completion date of May 2027; it was listed as not yet recruiting, with no results posted, in the March 2026 record. NAC CdLS trial

Neither trial is a gene therapy or a curative intervention. They test whether already available medicines can safely improve important neurobehavioral and functional outcomes while more definitive molecular approaches remain preclinical. CLoSER lithium trial NAC CdLS trial

Methodologies and Scientific Approaches

Researchers are combining animal models, patient-derived fibroblasts and blood cells, iPSCs, gene-edited isogenic control lines, neural precursor cells, and brain organoids. These platforms enable researchers to measure changes in cell survival, neuronal differentiation, chromatin organization, gene expression through RNA sequencing, and pathway activity after changing NIPBL, HDAC8, or WNT signaling. CRISPR-corrected CdLS stem cells Lithium in 2D and 3D CdLS models NIPBL iPSC hepatocyte model

Genetic diagnosis is also advancing. A 2025 whole-genome sequencing study of 105 previously “mutation-negative” CdLS-suspected families identified likely causal coding variants in 30.5% of families, including variants in NIPBL and genes that can resemble CdLS clinically. This helps define which people have cohesin-related CdLS versus overlapping developmental conditions, a necessary step for future gene-specific trials. Whole-genome sequencing in mutation-negative CdLS

Leading Institutions and Funding

The University of Milan and collaborating Italian institutions are central to the lithium program and associated human cellular and organoid studies, while Johns Hopkins University leads the NAC behavioral trial. The University of Trento and collaborators developed the published CRISPR correction platform for patient-derived CdLS iPSCs. CLoSER lithium trial NAC CdLS trial CRISPR-corrected CdLS stem cells

The Cornelia de Lange Syndrome Foundation provides family engagement, supports clinical research, and reports that it has awarded 24 small research grants totaling $300,000 since 2008. This foundation-scale support is valuable for a rare disorder, but it also illustrates the limited funding base available for the long, expensive work needed to develop and test gene-targeted therapies. CdLS Foundation research program

Strengths, Limitations, and Challenges

A major strength of the current field is that it has progressed from broad descriptions of a genetic syndrome to experimentally testable disease mechanisms. CRISPR-corrected patient cell lines can distinguish mutation-driven effects from background genetic variation, while neural organoids permit researchers to evaluate candidate therapies in more human-relevant systems than simple cell cultures. CRISPR-corrected CdLS stem cells Lithium in 2D and 3D CdLS models

The central challenge is biological complexity. CdLS can result from several genes, often begins before birth, and affects many organs; a treatment that improves a neural-cell phenotype may not correct growth, limb, gastrointestinal, cardiac, sensory, or developmental effects already established during fetal life. Lithium also requires careful clinical monitoring because it can affect kidney and thyroid function and has a narrow therapeutic range, while NAC and lithium trials are small and have not yet reported definitive CdLS outcomes. GeneReviews: Cornelia de Lange Syndrome CLoSER lithium trial NAC CdLS trial

Outlook and Future Directions

As of August 8, 2026, CdLS is not close to a proven cure, but the field has credible near-term milestones: results from CLoSER, initiation and completion of the NAC pilot, replication of lithium findings in genetically diverse patient-derived models, and development of safe in vivo delivery for mutation correction or gene-expression restoration. The most realistic first advances are likely to be therapies that improve particular developmental, behavioral, or medical outcomes; a whole-body curative therapy will require showing that a molecular intervention can be delivered safely, works across relevant tissues, and produces meaningful benefits for people with different CdLS-causing variants. CLoSER lithium trial CRISPR-corrected CdLS stem cells Whole-genome sequencing in mutation-negative CdLS

References

• GeneReviews: Cornelia de Lange Syndrome — University of Washington, Seattle / NCBI Bookshelf, 2026.
• CRISPR-corrected CdLS stem cells — Cereseto et al., 2022.
• Lithium as a CdLS therapeutic strategy — Parodi et al., 2021.
• Lithium in 2D and 3D CdLS models — Parodi et al., 2026.
• NAC CdLS trial — Johns Hopkins University, 2026.
• CLoSER lithium trial — University of Milan, 2025.
• NIPBL iPSC hepatocyte model — Barisani et al., 2024.
• Whole-genome sequencing in mutation-negative CdLS — Kline et al., 2025.
• CdLS Foundation research program — Cornelia de Lange Syndrome Foundation, 2026.